CRESTBRIDGE
25.7.2022 16:48:05 CEST | Business Wire | Press release
Crestbridge, the agile alternative for private equity and real estate administration solutions, today announced the appointment of Anne Catherine Grave as Country Head of Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005497/en/
Based in Luxembourg, Anne Catherine will be responsible for leading the business in the region and building on its reputation as a leading service provider for fund managers.
Since establishing a presence in Luxembourg 11 years ago, Crestbridge has continued its commitment to quality, evolving its service proposition in line with the jurisdiction’s own exponential growth. This is testament to Crestbridge’s popularity amongst fund managers, driven by the firm's expertise in management company services, private equity, real estate, private debt and venture capital.
Anne Catherine’s appointment adds further weight to Crestbridge’s highly experienced Luxembourg team, who provides global, comprehensive support to fund managers. This includes managing the administrative, accounting, reporting, residency and governance needs of a broad range of fund structures throughout their lifecycles.
Prior to joining Crestbridge, Anne Catherine was the Partner in charge of Corporate Secretarial Services in Deloitte in Luxembourg. She has over 20 years' experience in Private Equity and Real Estate sectors.
Anne Catherine gained her extensive experience as part of the Management/Executive Committees of Arendt Services in Luxembourg, as well as in her position as Executive Director of Bedell (which became Ocorian), a Luxembourg Trust & Fund business of a Jersey Group. In both positions, she served as board members of various regulated and non-regulated clients’ entities. Anne Catherine’s area of activities included the compliance, corporate, governance, tax, internal control and risk management functions. She started her career as tax advisor in Ernst & Young in Luxembourg and New York, before transitioning into a Senior Tax Lawyer position at a Luxembourg Law Firm, Arendt.
Anne Catherine holds masters’ degrees in economics and in International & European law, a post-graduate diplomas in Political Sciences as well as in International Business Law. She is also qualified as a Certified International Control Specialist and has a qualification in risk management. She was a Chartered Accountant in Luxembourg and a qualified attorney in France and Luxembourg. Anne Catherine was the Chair of the ILA Company Secretary and Governance Officer Committee for 4 years. She remains an active member of such committee and is a speaker for the ILA Company Secretary and Governance Officer Committee certification.
Michael Johnson, Group Head of Institutional Services, Crestbridge, said:
“I'm delighted to welcome Anne Catherine to the team and am delighted that Crestbridge continues to be a business where top, global talent comes to work and thrive. Anne Catherine will be leading some of the best talent available in the region, people who are focused on delivering exceptional service and innovative solutions to our global client base. Anne Catherine offers the team not only considerable technical expertise but vast knowledge, having worked with some of the biggest names in the industry. I look forward to her playing a vital role in leading and driving forward our Luxembourg and international business.”
-ENDS-
Notes to editors
- We are a leading global administration, management & corporate governance solutions business.
- We provide a broad range of outsourced fiduciary, administrative, accounting, and compliance services globally – our expertise spans services, asset classes, and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers, and ultra-high net worth families.
- Crestbridge employs over 500+ people and has nine international offices: Bahrain, Cayman, Ireland, Jersey, London, Luxembourg, New Jersey, New York, and Southampton.
- We are regulated in our locations (see here for more details)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
